Abstract

Background: This study was done to achieve a new drug delivery system delivering two different chemotherapy molecules to the target tissue simultaneously.
Significance: Co-delivery of chemotherapy medicines provides synergistic effects leading to lowering the dose of administered drugs and side effects.
Methods: Doxorubicin (DOX) was introduced to water-soluble hyaluronic acid (Hyal) using 1-amino-3,3-diethoxy-propane (ADEP), as a pH-sensitive linker, to develop a new hydrophobic structure, i.e. Hyal-ADEP-DOX. The conjugates were grafted in three ratios (7.5%, 12.5%, and 20%) to Hyal and characterized by Fourier transform infrared (FT-IR) and proton nuclear magnetic resonance (1HNMR). Cannabidiol (CBD) was physically loaded in the core of nano-micelles.
Results: Prepared nano-micelles were analyzed for critical micelle concentration (CMC) particle size stability and drug release before and after loading the CBD. Hyal-ADEP-DOX-12.5 was the optimized ratio and had a mean diameter of 50 nm before loading the CBD and 120 nm after loading (observed by transmission electron microscopy). The release results showed that DOX releases slowly in physiological pH, and CBD has a burst release at acidic pH from Hyal-ADEP-DOX-12.5. These properties altogether make Hyal-ADEP-DOX nano-micelles, as a stimuli-sensitive nano-carrier, a potential candidate for hydrophobic anticancer agents’ co-delivery.
Conclusion: The grafted DOX exhibited pH-sensitive release behavior, i.e. while 22.8% of the drug was released after 24 h at pH 5.5, and 5% was released after 24 h at pH 7.4. Hyal-ADEP-DOX due to its low CMC value, colloidal stability, slow drug release in physiological pH, and burst release in acidic pH Hyal-ADEP-DOX, is an excellent candidate as a carrier to co-deliver hydrophobic therapeutic agents to tumor tissues.

Keywords: Doxorubicin Cannabidiol Nano-micelle pH-sensitive Co-delivery References

1. Greish K, Mathur A, Al Zahrani R, Elkaissi S, Al Jishi M, Nazzal O, et al. Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer. Journal of Controlled Release. 2018;291:184-95.
2. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Advanced drug delivery reviews. 2004;56(11):1649-59.
3. Greish K, Mathur A, Al Zahrani R, Elkaissi S, Al Jishi M, Nazzal O, et al. Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer. Journal of controlled release : official journal of the Controlled Release Society. 2018;291:184-95.
4. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert opinion on drug metabolism & toxicology. 2008;4(2):205-23.
5. Stierlé V, Laigle A, Jollès B. Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs. Biochemical pharmacology. 2005;70(10):1424-30.
6. Fraguas-Sánchez A, Fernández-Carballido A, Simancas-Herbada R, Martin-Sabroso C, Torres-Suárez A. CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer. International journal of pharmaceutics. 2020;574:118916.
7. Grifoni L, Vanti G, Donato R, Sacco C, Bilia AR. Promising Nanocarriers to Enhance Solubility and Bioavailability of Cannabidiol for a Plethora of Therapeutic Opportunities. Molecules (Basel, Switzerland). 2022;27(18).
8. D'Aloia A, Ceriani M, Tisi R, Stucchi S, Sacco E, Costa B. Cannabidiol Antiproliferative Effect in Triple-Negative Breast Cancer MDA-MB-231 Cells Is Modulated by Its Physical State and by IGF-1. International journal of molecular sciences. 2022;23(13).
9. Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Molecular cancer therapeutics. 2014;13(12):2955-67.
10. Park JH, Kwon S, Lee M, Chung H, Kim J-H, Kim Y-S, et al. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials. 2006;27(1):119-26.
11. Zhou Y-Y, Du Y-Z, Wang L, Yuan H, Zhou J-P, Hu F-Q. Preparation and pharmacodynamics of stearic acid and poly (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles for 10-hydroxycamptothecin. International Journal of Pharmaceutics. 2010;393(1):144-52.
12. Shi J, Guobao W, Chen H, Zhong W, Qiu X, Xing MMQ. Schiff based injectable hydrogel for in situ pH-triggered delivery of doxorubicin for breast tumor treatment. Polymer Chemistry. 2014;5(21):6180-9.
13. Xiong X-B, Ma Z, Lai R, Lavasanifar A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials. 2010;31(4):757-68.
14. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release. 2000;65(1):271-84.
15. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T. Block Copolymer Design for Camptothecin Incorporation into Polymeric Micelles for Passive Tumor Targeting. Pharmaceutical Research. 2004;21(11):2001-8.
16. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation. 2001;41(1):189-207.
17. Zhang Y, Yang C, Wang W, Liu J, Liu Q, Huang F, et al. Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Scientific reports. 2016;6:21225.
18. Chang Q, Gao H, Bu S, Zhong W, Lu F, Xing M. An injectable aldehyded 1-amino-3, 3-diethoxy-propane hyaluronic acid–chitosan hydrogel as a carrier of adipose derived stem cells to enhance angiogenesis and promote skin regeneration. Journal of Materials Chemistry B. 2015;3(22):4503-13.
19. Liu J, Li H, Jiang X, Zhang C, Ping Q. Novel pH-sensitive chitosan-derived micelles loaded with paclitaxel. Carbohydrate Polymers. 2010;82(2):432-9.
20. Delplace V, Couvreur P, Nicolas J. Recent trends in the design of anticancer polymer prodrug nanocarriers. Polymer Chemistry. 2014;5(5):1529-44.
21. She W, Li N, Luo K, Guo C, Wang G, Geng Y, et al. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials. 2013;34(9):2252-64.
22. Tajani B, Tahvilian R, Khazaei S, Javadi KS, Fattahi A, editors. Preparation and Characterization of Camptothecin Grafted Chitosan Oligosaccharide Nanomicelles2015.
23. Tahvilian R, Tajani B, Sadrjavadi K, Fattahi A. Preparation and characterization of pH-sensitive camptothecin-cis-aconityl grafted chitosan oligosaccharide nanomicelles. International journal of biological macromolecules. 2016;92:795-802.
24. Stuart MC, van de Pas JC, Engberts JB. The use of Nile Red to monitor the aggregation behavior in ternary surfactant–water–organic solvent systems. Journal of physical organic chemistry. 2005;18(9):929-34.
25. Woraphatphadung T, Sajomsang W, Rojanarata T, Ngawhirunpat T, Tonglairoum P, Opanasopit P. Development of Chitosan-Based pH-Sensitive Polymeric Micelles Containing Curcumin for Colon-Targeted Drug Delivery. AAPS PharmSciTech. 2018;19(3):991-1000.
26. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release. Pharmaceutical Research. 2010;27(12):2569-89.
27. Fattahi A, Golozar M-A, Varshosaz J, Sadeghi HM, Fathi M. Preparation and characterization of micelles of oligomeric chitosan linked to all-trans retinoic acid. Carbohydrate Polymers. 2012;87(2):1176-84.
28. Du Y. A review of structural equation modeling and its use in library and information studies. Library & Information Science Research. 2009;31(4):257-63.
29. Giacomelli C, Schmidt V, Borsali R. Nanocontainers Formed by Self-Assembly of Poly(ethylene oxide)-b-poly(glycerol monomethacrylate)−Drug Conjugates. Macromolecules. 2007;40(6):2148-57.